Article
Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Thrombosis and haemostasis - 1 Sept 2011
Alessi Marie-Christine, Nicaud Viviane, Scroyen Ilse, Lange Celine, Saut Noemie, Fumeron Frederic, Marre Michel, Lantieri Olivier, Fontaine-Bisson Benedicte, Juhan-Vague Iréne, Balkau Beverley, Tregouet David-Alexandre, Morange Pierre-Emmanuel
Abstract excerpt
It was the objective of this study to investigate the relation between vitronectin and plasminogen activator inhibitor (PAI)-1 plasma levels with nine-year incidences of the metabolic syndrome (MetS) and of type 2 diabetes mellitus (T2DM). Baseline plasma concentrations of vitronectin and PAI-1 were measured in 627 healthy participants from the prospective D.E.S.I.R. cohort who subsequently developed MetS (n =...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
